Inhibitory potency of Valsartan/Sacubitril drug combination: molecular docking simulations

被引:0
|
作者
Jovanovic, Jelena Dorovic [1 ,2 ]
Markovic, Zoran [2 ]
Kokanovic, Mihajlo [1 ]
Filipovic, Nenad [3 ]
Stanojevic, Ma Rijana [4 ]
机构
[1] Bioengn Res & Dev Ctr BioIRC, Kragujevac, Serbia
[2] Univ Kragujevac, Inst Informat Technol, Dept Sci, Kragujevac 34000, Serbia
[3] Univ Kragujevac, Fac Engn, Bioengn Res & Dev Ctr, Kragujevac, Serbia
[4] Univ Kragujevac, Fac Med Sci, Pirkov Dept Biochem, Kragujevac 34000, Serbia
基金
欧盟地平线“2020”;
关键词
Entresto; molecular docking simulations; Neprilysin; Angiotensin II receptor;
D O I
10.1109/BIBE52308.2021.9635185
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Heart failure (HF) is a condition that affects mostly older populations. It can be treated with different medications, and one of them is Entresto. This is a medication which is consisting of two drugs, sacubitril (SAC) and valsartan (VAL). Here, in this study, are performed molecular docking simulations in order to examine the inhibitory potency of SAC and VAL towards neprilysin (NEP) and angiotensin II receptor (AT2), respectively. The achieved thermodynamic parameters shows that SAC and VAL can bind to targeted protein, and inhibit NEP and AT2. The best binding sites are determined. Also, the amino acids responsible for binding are identified.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] In vitro monoamine oxidase A and B inhibitory activity and molecular docking simulations of fucoxanthin
    Hyun Ah Jung
    Anupom Roy
    Jae Sue Choi
    Fisheries Science, 2017, 83 : 123 - 132
  • [22] In vitro monoamine oxidase A and B inhibitory activity and molecular docking simulations of fucoxanthin
    Jung, Hyun Ah
    Roy, Anupom
    Choi, Jae Sue
    FISHERIES SCIENCE, 2017, 83 (01) : 123 - 132
  • [23] An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension
    Wehland, Markus
    Simonsen, Ulf
    Buus, Niels Henrik
    Krueger, Marcus
    Grimm, Daniela
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (10) : 1133 - 1143
  • [24] Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
    Lee, Ying-Hsiang
    Lin, Po-Lin
    Chiou, Wei-Ru
    Huang, Jin-Long
    Lin, Wen-Yu
    Liao, Chia-Te
    Chung, Fa-Po
    Liang, Huai-Wen
    Hsu, Chien-Yi
    Chang, Hung-Yu
    ESC HEART FAILURE, 2021, 8 (02): : 1204 - 1215
  • [25] Predicting HLA-Specific Drug Hypersensitivity with Molecular Docking and Molecular Dynamics Simulations
    Yao, Xin-Qiu
    Grant, Barry J.
    BIOPHYSICAL JOURNAL, 2014, 106 (02) : 411A - 411A
  • [26] Variation in Early Diffusion of Sacubitril/Valsartan and Implications for Understanding Novel Drug Diffusion
    Gilstrap, Lauren
    King, Ashleigh
    Tomlin, Stephanie
    Austin, Andrea M.
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (12): : 524 - +
  • [27] Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan)
    Eadie, Ashley L.
    Brunt, Keith R.
    Herder, Matthew
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (03):
  • [28] Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan
    Sunaga, Tomiko
    Ryo, Yonezawa
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 166 : 127 - 130
  • [29] Serious adverse drug reactions with sacubitril/valsartan EntrestoA®: a French pharmacovigilance survey
    Moulis, Florence
    Rousseau, Vanessa
    Chebane, Leila
    Gouverneur, Amandine
    Gaboriau, Louise
    Faillie, Jean-Luc
    Durrieu, Genevieve
    Montastruc, Francois
    Montastruc, Jean-Louis
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (07) : 983 - 984
  • [30] Molecular Docking and Molecular Dynamics Simulations of the Urease Inhibitory Activity of 2,3-Dihydroxybenzohydrazide Derivatives
    Wang, Yueru
    Dang, Xiaolin
    Zhang, Jingxiao
    Tong, Hongjuan
    Tang, Wenqiang
    Liu, Bin
    CHEMISTRYSELECT, 2024, 9 (37):